^
    30d
    Multicenter Trial of ESK981 in Patients With Select Solid Tumors (clinicaltrials.gov)
    P2, N=66, Recruiting, University of Michigan Rogel Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    SYP (Synaptophysin) • CHGA (Chromogranin A)
    |
    ESK981
    2ms
    Multicenter Trial of ESK981 in Patients With Select Solid Tumors (clinicaltrials.gov)
    P2, N=66, Not yet recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Jan 2029 --> May 2029 | Initiation date: Jan 2024 --> May 2024 | Trial primary completion date: Jan 2027 --> May 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    SYP (Synaptophysin) • CHGA (Chromogranin A)
    |
    ESK981
    6ms
    Multicenter Trial of ESK981 in Patients With Select Solid Tumors (clinicaltrials.gov)
    P2, N=66, Not yet recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Sep 2028 --> Jan 2029 | Initiation date: Oct 2023 --> Jan 2024 | Trial primary completion date: Aug 2026 --> Jan 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    SYP (Synaptophysin) • CHGA (Chromogranin A)
    |
    ESK981
    9ms
    Multicenter Trial of ESK981 in Patients With Select Solid Tumors (clinicaltrials.gov)
    P2, N=66, Not yet recruiting, University of Michigan Rogel Cancer Center
    New P2 trial
    |
    SYP (Synaptophysin) • CHGA (Chromogranin A)
    |
    ESK981
    10ms
    ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=13, Completed, Barbara Ann Karmanos Cancer Institute | Active, not recruiting --> Completed | N=27 --> 13
    Trial completion • Enrollment change • Metastases
    |
    ESK981
    over2years
    Autophagy Inhibition by Targeting PIKfyve Potentiates Response to Immune Checkpoint Blockade in Prostate Cancer. (PubMed, Nat Cancer)
    PIKfyve-knockdown recapitulated ESK981's anti-tumor activity and enhanced the therapeutic benefit of immune checkpoint blockade. Our study reveals that targeting PIKfyve via ESK981 turns tumors from cold into hot through inhibition of autophagy, which may prime the tumor immune microenvironment in advanced prostate cancer patients and be an effective treatment strategy alone or in combination with immunotherapies.
    Journal • Checkpoint inhibition • IO biomarker
    |
    IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10)
    |
    ESK981